pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Oncology · news · pharmadog
← back to Oncology
News · Oncology
1,487
stories
4d
Weighing the risks of CAR T in autoimmune disease as Kyverna nears market
biospace
4d
Weighing the risks of CAR T in autoimmune disease as Kyverna nears market
biospace
4d
Genmab’s latest phase 2 data spur claim ADC is ‘clearly superior’ to AbbVie’s Elahere
fiercebiotech
4d
Opinion: FDA must ensure American patients can access new and experimental drugs
biospace
4d
Swiss CDMOs and CROs ride a new wave of growth amid surge in global demand
biospace
4d
IV Tubing Set Correction: ICU Medical Updates Use Instructions for IV Tubing Sets
fda medwatch
6d
NIH rolling out streamlined website to help public find information more easily
stat
6d
What it’s like to wait for the call from the Nobel Prize committee
stat
6d
BMO most bullish on Merck's, bearish on BMS’ plans to contend with patent cliffs
biospace
6d
Summit partners with AstraZeneca and Daiichi; Eccogene earns $50M milestone
endpoints
6d
Moderna, Neurocrine bring back familiar faces; Pharming CEO exits after clashing with board
endpoints
6d
‘We’ve been taking our time’: Buzzy AI biotech Xaira reveals antibody platform, first taste of pipeline
fiercebiotech
7d
Novartis takes rights to Abogen's mRNA T cell engager for $575M upfront
endpoints
7d
Novartis pens $7.8B deal for Abogen's in vivo autoimmune T-cell engager
fiercebiotech
7d
Immunotherapy startup Adecto blames ‘risk-averse funding environment’ for closing down
fiercebiotech
7d
Abbott launches SimpleScreen CRC blood test in the US
fiercebiotech
7d
STAT+: Medicare Advantage plans shift more costs onto seniors in 2027
stat
7d
Chutes & Ladders—Bayer taps new chief medical officer; Cantor appointed PhRMA CEO
fiercebiotech
7d
Lilly, Foghorn part ways; Wave’s FDA-approved plans
biopharma dive
7d
Foghorn lays off 40% of staff after Lilly collaboration ends
biospace
8d
Foghorn lays off 40% of employees as Lilly cancer collab collapses over poor data
fiercebiotech
8d
Opinion: Claude analyzed my genome in 30 minutes. Now we need standards for the results
stat
8d
The top 12 companies hiring in biopharma now
biospace
8d
FDA starts review of Roche’s multiple sclerosis pill
biopharma dive
8d
AbbVie's eczema drug shows benefit in Phase 2; BioMarin lays off 117
endpoints
8d
Rural MAHA followers say Trump hasn’t improved health of their communities, poll finds
stat
8d
STAT+: Three biotech updates, including accusations of theft and and a new lobbying leader
stat
8d
FDA Launches Nationwide Effort to Expand Scientific Expertise and Consumer Voices to Advisory Committees
fda press
8d
An AI agent made a tiny drug R&D mistake. Then it kept going.
biopharma dive
8d
Ned Sharpless joins Hatteras, as Andrew Witty returns to the VC firm as chairman
endpoints
← prev
page 3 of 50
next →
